Executive Summary
Napo Pharmaceuticals focuses on the development and commercialisation of proprietary pharmaceuticals for the global marketplace in collaboration with local partners. Napo?s late stage proprietary gastro-intestinal compound, crofelemer, is in various stages of clinical development for four distinct product indications. One product is in Phase 3, two in Phase 2 and one in Phase 1 clinical trials. There are four indications - AIDS diarrhoea, Irritable Bowel Syndrome (IBS), acute infectious diarrhoea (traveller?s diarrhoea and cholera) and paediatric diarrhoea.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
